Breast cancer survival in the US and Europe

A CONCORD high-resolution study

Claudia Allemani, Milena Sant, Hannah K. Weir, Lisa C. Richardson, Paolo Baili, Hans Storm, Sabine Siesling, Ana Torrella-Ramos, Adri C. Voogd, Tiiu Aareleid, Eva Ardanaz, Franco Berrino, Magdalena Bielska-Lasota, Susan Bolick, Claudia Cirilli, Marc Colonna, Paolo Contiero, Rosemary D Cress, Emanuele Crocetti, John P. Fulton & 20 others Pascale Grosclaude, Timo Hakulinen, M. Isabel Izarzugaza, Per Malmström, Karin Peignaux, Maja Primic-Žakelj, Jadwiga Rachtan, Chakameh Safaei Diba, Maria José Sánchez, Maria J. Schymura, Tiefu Shen, Adele Traina, Laufey Tryggvadottir, Rosario Tumino, Michel Velten, Marina Vercelli, Holly J. Wolf, Anne Sophie Woronoff, Xiaocheng Wu, Michel P. Coleman

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.

Original languageEnglish (US)
Pages (from-to)1170-1181
Number of pages12
JournalInternational Journal of Cancer
Volume132
Issue number5
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Breast Neoplasms
Survival
Eastern Europe
Neoplasms
Health Expenditures
Registries
Delivery of Health Care
Therapeutics
Population

Keywords

  • cancer registries
  • CONCORD
  • excess hazard
  • net survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Allemani, C., Sant, M., Weir, H. K., Richardson, L. C., Baili, P., Storm, H., ... Coleman, M. P. (2013). Breast cancer survival in the US and Europe: A CONCORD high-resolution study. International Journal of Cancer, 132(5), 1170-1181. https://doi.org/10.1002/ijc.27725

Breast cancer survival in the US and Europe : A CONCORD high-resolution study. / Allemani, Claudia; Sant, Milena; Weir, Hannah K.; Richardson, Lisa C.; Baili, Paolo; Storm, Hans; Siesling, Sabine; Torrella-Ramos, Ana; Voogd, Adri C.; Aareleid, Tiiu; Ardanaz, Eva; Berrino, Franco; Bielska-Lasota, Magdalena; Bolick, Susan; Cirilli, Claudia; Colonna, Marc; Contiero, Paolo; Cress, Rosemary D; Crocetti, Emanuele; Fulton, John P.; Grosclaude, Pascale; Hakulinen, Timo; Izarzugaza, M. Isabel; Malmström, Per; Peignaux, Karin; Primic-Žakelj, Maja; Rachtan, Jadwiga; Safaei Diba, Chakameh; Sánchez, Maria José; Schymura, Maria J.; Shen, Tiefu; Traina, Adele; Tryggvadottir, Laufey; Tumino, Rosario; Velten, Michel; Vercelli, Marina; Wolf, Holly J.; Woronoff, Anne Sophie; Wu, Xiaocheng; Coleman, Michel P.

In: International Journal of Cancer, Vol. 132, No. 5, 01.03.2013, p. 1170-1181.

Research output: Contribution to journalArticle

Allemani, C, Sant, M, Weir, HK, Richardson, LC, Baili, P, Storm, H, Siesling, S, Torrella-Ramos, A, Voogd, AC, Aareleid, T, Ardanaz, E, Berrino, F, Bielska-Lasota, M, Bolick, S, Cirilli, C, Colonna, M, Contiero, P, Cress, RD, Crocetti, E, Fulton, JP, Grosclaude, P, Hakulinen, T, Izarzugaza, MI, Malmström, P, Peignaux, K, Primic-Žakelj, M, Rachtan, J, Safaei Diba, C, Sánchez, MJ, Schymura, MJ, Shen, T, Traina, A, Tryggvadottir, L, Tumino, R, Velten, M, Vercelli, M, Wolf, HJ, Woronoff, AS, Wu, X & Coleman, MP 2013, 'Breast cancer survival in the US and Europe: A CONCORD high-resolution study', International Journal of Cancer, vol. 132, no. 5, pp. 1170-1181. https://doi.org/10.1002/ijc.27725
Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H et al. Breast cancer survival in the US and Europe: A CONCORD high-resolution study. International Journal of Cancer. 2013 Mar 1;132(5):1170-1181. https://doi.org/10.1002/ijc.27725
Allemani, Claudia ; Sant, Milena ; Weir, Hannah K. ; Richardson, Lisa C. ; Baili, Paolo ; Storm, Hans ; Siesling, Sabine ; Torrella-Ramos, Ana ; Voogd, Adri C. ; Aareleid, Tiiu ; Ardanaz, Eva ; Berrino, Franco ; Bielska-Lasota, Magdalena ; Bolick, Susan ; Cirilli, Claudia ; Colonna, Marc ; Contiero, Paolo ; Cress, Rosemary D ; Crocetti, Emanuele ; Fulton, John P. ; Grosclaude, Pascale ; Hakulinen, Timo ; Izarzugaza, M. Isabel ; Malmström, Per ; Peignaux, Karin ; Primic-Žakelj, Maja ; Rachtan, Jadwiga ; Safaei Diba, Chakameh ; Sánchez, Maria José ; Schymura, Maria J. ; Shen, Tiefu ; Traina, Adele ; Tryggvadottir, Laufey ; Tumino, Rosario ; Velten, Michel ; Vercelli, Marina ; Wolf, Holly J. ; Woronoff, Anne Sophie ; Wu, Xiaocheng ; Coleman, Michel P. / Breast cancer survival in the US and Europe : A CONCORD high-resolution study. In: International Journal of Cancer. 2013 ; Vol. 132, No. 5. pp. 1170-1181.
@article{8c335efa21ad42ec9e4424bb8690886e,
title = "Breast cancer survival in the US and Europe: A CONCORD high-resolution study",
abstract = "Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39{\%}) than in Europe (32{\%}), while locally advanced tumors were twice as frequent in Europe (8{\%}), and metastatic tumors of similar frequency (5-6{\%}). Net survival in Northern, Western and Southern Europe (81-84{\%}) was similar to that in the US (84{\%}), but lower in Eastern Europe (69{\%}). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.",
keywords = "cancer registries, CONCORD, excess hazard, net survival",
author = "Claudia Allemani and Milena Sant and Weir, {Hannah K.} and Richardson, {Lisa C.} and Paolo Baili and Hans Storm and Sabine Siesling and Ana Torrella-Ramos and Voogd, {Adri C.} and Tiiu Aareleid and Eva Ardanaz and Franco Berrino and Magdalena Bielska-Lasota and Susan Bolick and Claudia Cirilli and Marc Colonna and Paolo Contiero and Cress, {Rosemary D} and Emanuele Crocetti and Fulton, {John P.} and Pascale Grosclaude and Timo Hakulinen and Izarzugaza, {M. Isabel} and Per Malmstr{\"o}m and Karin Peignaux and Maja Primic-Žakelj and Jadwiga Rachtan and {Safaei Diba}, Chakameh and S{\'a}nchez, {Maria Jos{\'e}} and Schymura, {Maria J.} and Tiefu Shen and Adele Traina and Laufey Tryggvadottir and Rosario Tumino and Michel Velten and Marina Vercelli and Wolf, {Holly J.} and Woronoff, {Anne Sophie} and Xiaocheng Wu and Coleman, {Michel P.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1002/ijc.27725",
language = "English (US)",
volume = "132",
pages = "1170--1181",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Breast cancer survival in the US and Europe

T2 - A CONCORD high-resolution study

AU - Allemani, Claudia

AU - Sant, Milena

AU - Weir, Hannah K.

AU - Richardson, Lisa C.

AU - Baili, Paolo

AU - Storm, Hans

AU - Siesling, Sabine

AU - Torrella-Ramos, Ana

AU - Voogd, Adri C.

AU - Aareleid, Tiiu

AU - Ardanaz, Eva

AU - Berrino, Franco

AU - Bielska-Lasota, Magdalena

AU - Bolick, Susan

AU - Cirilli, Claudia

AU - Colonna, Marc

AU - Contiero, Paolo

AU - Cress, Rosemary D

AU - Crocetti, Emanuele

AU - Fulton, John P.

AU - Grosclaude, Pascale

AU - Hakulinen, Timo

AU - Izarzugaza, M. Isabel

AU - Malmström, Per

AU - Peignaux, Karin

AU - Primic-Žakelj, Maja

AU - Rachtan, Jadwiga

AU - Safaei Diba, Chakameh

AU - Sánchez, Maria José

AU - Schymura, Maria J.

AU - Shen, Tiefu

AU - Traina, Adele

AU - Tryggvadottir, Laufey

AU - Tumino, Rosario

AU - Velten, Michel

AU - Vercelli, Marina

AU - Wolf, Holly J.

AU - Woronoff, Anne Sophie

AU - Wu, Xiaocheng

AU - Coleman, Michel P.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.

AB - Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.

KW - cancer registries

KW - CONCORD

KW - excess hazard

KW - net survival

UR - http://www.scopus.com/inward/record.url?scp=84872849005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872849005&partnerID=8YFLogxK

U2 - 10.1002/ijc.27725

DO - 10.1002/ijc.27725

M3 - Article

VL - 132

SP - 1170

EP - 1181

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -